
SUPPLEMENTARY MATERIALS

Title: Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment

Authors:

Pasquale Aragona¹, Giuseppe Giannaccare⁵, Edoardo Dammino³, Fabiana D'Esposito⁴, Paola Genovese¹, Elisa Imelde Postorino¹, Claudine Civiale², Maria Grazia Mazzone², Caterina Gagliano⁵

Affiliations:

¹ Dept. of Biomedical Sciences, Ophthalmology Clinic, University of Messina, Messina, Italy.

² SIFI S.p.A., Via Ercole Patti 36, 95025, Aci San Antonio, Catania, Italy.

³ Faculty of Medicine, University of Catania, Piazza Università, 95123 Catania, Italy.

⁴ Imperial College Ophthalmic Research Group Unit, Imperial College, London SW7 2AZ, U.K; Eye Clinic, Department of Neurosciences, Reproductive Sciences and Dentistry, University of Naples Federico II, 80100 Naples, Italy; Genofta s.r.l., Sant'Agnello, 80065 Naples, Italy.

⁵ University of Cagliari, Ophthalmology Residency Program Eye Clinic, Via Università, 40, 09124, Cagliari, Italy.

⁶ University of Enna "Kore", Department of Medicine and Surgery, Piazza dell'Università, 94100, Enna; San Marco Hospital, Viale Carlo Azeglio Ciampi, 95100, Catania, Italy.

Co-corresponding authors:

Full name: Prof. Pasquale Aragona MD, PhD; ORCID: 0000-0002-9582-9799

Department/Institute/University/Hospital: Prof. Ordinario di Oftalmologia, Direttore Unità Operativa Complessa (U.O.C.) di Oftalmologia, Direttore Scuola di Specializzazione in Oftalmologia, Dipartimento di Scienze Biomediche, Università degli Studi di Messina

Street Name & Number, City (State), Postal code, Country: Messina, Italia

Tel: +39 3483384677

E-mail: pasquale.aragona@unime.it

Full name: Dr. Claudine Civiale PharmD

Department/Institute/University/Hospital: SIFI S.p.A.; Street Name & Number, City (State), Postal code, Country: Via Ercole Patti 36, 95025 Aci San Antonio (CT) Italy

Tel: +39 3356864618

E-mail: claudine.civiale@sifigroup.com

Supplementary Table 1. Results obtained by evaluating the 12 subscales of NEI-VFQ25 (ITT population).

Endpoint	Measures	Ophthalmic solution	Paired t-test (p-value)
General health at Visit 1 (n=19)	Mean (SD)	51.57 (19.68)	
	Median (range)	52.50 (22.50-87.50)	
General health at Visit 3 (n=19)	Mean (SD)	56.44 (23.75)	
	Median (range)	55.00 (15.00-87.50)	
Change Visit 3 vs Visit 1 (n=19)	Mean (SD)	4.86 (17.22)	0.2339
	Range	-27.50-35.00	
General vision at Visit 1 (n=19)	Mean (SD)	60.78 (18.42)	
	Median (range)	65.00 (25.00-90.00)	
General vision at Visit 3 (n=19)	Mean (SD)	72.10 (20.16)	
	Median (range)	80.00 (15.00-87.50)	
Change Visit 3 vs Visit 1 (n=19)	Mean (SD)	11.31 (13.10)	0.0014 ¹
	Range	-10.00-35.00	
Ocular pain at Visit 1 (n=25)	Mean (SD)	57.00 (22.26)	
	Median (range)	50.00 (12.50-100.00)	
Ocular pain at Visit 3 (n=25)	Mean (SD)	72.00 (27.07)	
	Median (range)	75.00 (12.20-100.00)	
Change Visit 3 vs Visit 1 (n=25)	Mean (SD)	15.00 (21.65)	0.0020 ¹
	Range	-25.00-62.50	
Near activities at Visit 1 (n=17)	Mean (SD)	79.16 (18.22)	
	Median (range)	83.33 (33.33-100.00)	
Near activities at Visit 3 (n=17)	Mean (SD)	90.98(13.15)	
	Median (range)	100.00 (62.50-100.00)	
Change Visit 3 vs Visit 1 (n=17)	Mean (SD)	11.81 (10.69)	0.0003 ¹
	Range	0.00-33.33	
Distance activities at Visit 1 (n=19)	Mean (SD)	82.89 (17.11)	
	Median (range)	87.50 (41.66-100.00)	
Distance activities at Visit 3 (n=19)	Mean (SD)	90.00(16.03)	
	Median (range)	100.00 (50.00-100.00)	
Change Visit 3 vs Visit 1 (n=19)	Mean (SD)	7.105 (11.30)	0.0135
	Range	-20.83-29.16	
Social functioning at Visit 1 (n=20)	Mean (SD)	95.00 (10.25)	
	Median (range)	100.00 (58.33-100.00)	
Social functioning at Visit 3 (n=20)	Mean (SD)	97.08(6.77)	
	Median (range)	100.00 (75.00-100.00)	
Change Visit 3 vs Visit 1 (n=20)	Mean (SD)	2.08 (11.10)	0.4120
	Range	-16.00-33.33	
Mental health at Visit 1 (n=22)	Mean (SD)	70.68 (22.79)	
	Median (range)	70.00 (35.00-100.00)	
Mental health at Visit 3 (n=22)	Mean (SD)	83.40 (16.45)	
	Median (range)	87.50 (50.00-100.00)	
Change Visit 3 vs Visit 1 (n=22)	Mean (SD)	12.72 (20.10)	0.0073
	Range	-21.25-55.00	

Role difficulties at Visit 1 (n=20)	Mean (SD)	80.93 (16.65)	
	Median (range)	81.25 (50.00-100.00)	
Role difficulties at Visit 3 (n=20)	Mean (SD)	88.12 (20.26)	
	Median (range)	100 (31.25-100.00)	
Change Visit 3 vs Visit 1 (n=20)	Mean (SD)	7.18 (18.72)	0.1023
	Range	-43.75-37.50	
Dependency at Visit 1 (n=20)	Mean (SD)	91.25 (14.39)	
	Median (range)	100.00 (56.25-100.00)	
Dependency at Visit 3 (n=20)	Mean (SD)	93.22 (17.89)	
	Median (range)	100.00 (25.00-100.00)	
Change Visit 3 vs Visit 1 (n=20)	Mean (SD)	1.97 (10.97)	0.4298
	Range	-31.25-18.75	
Driving at Visit 1 (n=20)	Mean (SD)	70.83 (19.20)	
	Median (range)	75.00 (8.33-91.66)	
Driving at Visit 3 (n=20)	Mean (SD)	80.30 (18.32)	
	Median (range)	83.33 (33.33-100.00)	
Change Visit 3 vs Visit 1 (n=20)	Mean (SD)	9.467 (18.19)	0.00236
	Range	-29.16-41.66	
Color vision at Visit 1 (n=25)	Mean (SD)	93.00 (16.95)	
	Median (range)	100.00 (25.00-100.00)	
Color vision at Visit 3 (n=25)	Mean (SD)	98.00 (6.92)	
	Median (range)	100.00 (75.00-100.00)	
Change Visit 3 vs Visit 1 (n=25)	Mean (SD)	5.00 (16.13)	0.1344
	Range	-25.00-50.00	
Peripheral vision at Visit 1 (n=25)	Mean (SD)	85.00 (23.93)	
	Median (range)	100.00 (25.00-100.00)	
Peripheral vision at Visit 3 (n=25)	Mean (SD)	89.00 (19.20)	
	Median (range)	100.00 (50.00-100.00)	
Change Visit 3 vs Visit 1 (n=25)	Mean (SD)	4.00 (13.84)	0.1615
	Range	-25.00-50.00	

¹ Statistically significant.

ITT, intention-to-treat; NEI-VFQ-25, National Eye Institute Vision Function Questionnaire-25; SD, standard deviation; Visit 1, baseline; Visit 3, study termination visit.